EVMN
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Evommune, Inc. (EVMN) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Momentum (D-). The rating has held at C for 14 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.8) | D+ (1.8) | B- (2.9) | D- (0.9) | C+ (2.6) | C (2.2) |
| 2026-11-04 | B- (2.9) | D+ (1.7) | B- (2.9) | D- (0.8) | C+ (2.7) | C (2.2) |
| 2026-10-28 | B (3.3) | D+ (1.7) | B- (2.9) | D- (0.8) | C+ (2.7) | C (2.3) |
| 2026-10-21 | B- (2.9) | D+ (1.7) | B- (3.0) | D- (0.9) | C+ (2.6) | C (2.2) |
| 2026-10-14 | B- (2.9) | D+ (1.7) | B- (3.0) | D- (1.0) | C+ (2.6) | C (2.2) |